A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. (Q51855572)
Jump to navigation
Jump to search
scientific article published in March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. |
scientific article published in March 2014 |
Statements
1 reference
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. (English)
1 reference
Jürgen K Rockstroh
1 reference
Jean-Michel Molina
1 reference
Joseph Gathe
1 reference
Marshall W Fordyce
1 reference
Javier Szwarcberg
1 reference
GS-236-0103 Study Team
1 reference
Nathan Clumeck
1 reference
Keith Henry
1 reference
Edwin DeJesus
1 reference
Xuelian Wei
1 reference
Kirsten White
1 reference
Martin S Rhee
1 reference
1 March 2014
1 reference
65
1 reference
3
1 reference
e121-4
1 reference
Identifiers
1 reference